Fennec Pharmaceuticals Inc.

NasdaqCM:FENC Stock Report

Market Cap: US$164.3m

Fennec Pharmaceuticals Management

Management criteria checks 2/4

Fennec Pharmaceuticals' CEO is Rosty Raykov, appointed in Jul 2009, has a tenure of 15.42 years. total yearly compensation is $2.54M, comprised of 23.9% salary and 76.1% bonuses, including company stock and options. directly owns 0.24% of the company’s shares, worth $397.93K. The average tenure of the management team and the board of directors is 4.6 years and 10.7 years respectively.

Key information

Rosty Raykov

Chief executive officer

US$2.5m

Total compensation

CEO salary percentage23.9%
CEO tenure15.4yrs
CEO ownership0.2%
Management average tenure4.6yrs
Board average tenure10.7yrs

Recent management updates

Recent updates

Improved Revenues Required Before Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Stock's 25% Jump Looks Justified

Nov 24
Improved Revenues Required Before Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Stock's 25% Jump Looks Justified

Revenues Working Against Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) Share Price

Oct 04
Revenues Working Against Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) Share Price

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Analysts Are More Bearish Than They Used To Be

Aug 15
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Analysts Are More Bearish Than They Used To Be

Is Fennec Pharmaceuticals (NASDAQ:FENC) A Risky Investment?

Jul 16
Is Fennec Pharmaceuticals (NASDAQ:FENC) A Risky Investment?

Lacklustre Performance Is Driving Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) 27% Price Drop

Jun 02
Lacklustre Performance Is Driving Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) 27% Price Drop

Risks To Shareholder Returns Are Elevated At These Prices For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

Apr 18
Risks To Shareholder Returns Are Elevated At These Prices For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

Earnings Update: Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Just Reported And Analysts Are Boosting Their Estimates

Nov 09
Earnings Update: Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Just Reported And Analysts Are Boosting Their Estimates

Fennec wins FDA approval of Pedmark for chemotherapy-induced ototoxicity in children

Sep 20

Buying Fennec Pharma Ahead Of September PDUFA For Pedmark

Aug 23

Fennec Pharmaceuticals secures up to $45M financing facility from Petrichor

Aug 01

Fennec Pharmaceuticals: Will Pedmark Make It To Market At Second Time Of Asking?

Oct 29

Fennec Could See Upside If Pedmark Gets Approved

Jul 29

Fennec Pharmaceuticals (FENC) Investor Presentation - Slideshow

Jun 18

Fennec Pharma resubmits PEDMARK application in U.S.

May 28

Fennec Pharmaceuticals (NASDAQ:FENC) Is In A Good Position To Deliver On Growth Plans

May 26
Fennec Pharmaceuticals (NASDAQ:FENC) Is In A Good Position To Deliver On Growth Plans

Breakeven On The Horizon For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

Apr 01
Breakeven On The Horizon For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

CEO Compensation Analysis

How has Rosty Raykov's remuneration changed compared to Fennec Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$1m

Jun 30 2024n/an/a

US$3m

Mar 31 2024n/an/a

US$3m

Dec 31 2023US$3mUS$607k

-US$16m

Sep 30 2023n/an/a

-US$20m

Jun 30 2023n/an/a

-US$26m

Mar 31 2023n/an/a

-US$26m

Dec 31 2022US$614kUS$503k

-US$24m

Sep 30 2022n/an/a

-US$21m

Jun 30 2022n/an/a

-US$17m

Mar 31 2022n/an/a

-US$16m

Dec 31 2021US$3mUS$468k

-US$17m

Sep 30 2021n/an/a

-US$16m

Jun 30 2021n/an/a

-US$18m

Mar 31 2021n/an/a

-US$19m

Dec 31 2020US$2mUS$430k

-US$18m

Sep 30 2020n/an/a

-US$18m

Jun 30 2020n/an/a

-US$14m

Mar 31 2020n/an/a

-US$14m

Dec 31 2019US$1mUS$489k

-US$13m

Sep 30 2019n/an/a

-US$12m

Jun 30 2019n/an/a

-US$13m

Mar 31 2019n/an/a

-US$11m

Dec 31 2018US$1mUS$350k

-US$10m

Sep 30 2018n/an/a

-US$9m

Jun 30 2018n/an/a

-US$9m

Mar 31 2018n/an/a

-US$8m

Dec 31 2017US$450kUS$263k

-US$7m

Compensation vs Market: Rosty's total compensation ($USD2.54M) is above average for companies of similar size in the US market ($USD1.41M).

Compensation vs Earnings: Rosty's compensation has increased whilst the company is unprofitable.

CEO

Rosty Raykov (48 yo)

15.4yrs

Tenure

US$2,540,940

Compensation

Mr. Rostislav Raykov, also known as Rosty, has been the Chief Executive Officer of c Pharmaceuticals Inc. since July 2009. Mr. Raykov is an Independent Director of Lavras Gold Corp. since April 1, 2022. Mr...

Leadership Team

NamePositionTenureCompensationOwnership
Rostislav Raykov
CEO & Director15.4yrsUS$2.54m0.24%
$ 397.9k
Robert Andrade
Chief Financial Officer9.1yrsUS$1.31m0.47%
$ 769.2k
Terry Evans
Chief Commercial Officerless than a yearno datano data
Pierre Sayad
Chief Medical Officerless than a yearno datano data
Christiana Cioffi
Chief Strategy Officerless than a yearno datano data
Mark Gowland
Controller9.1yrsno datano data
Lei Fang
President of Pharstat Incno datano datano data

4.6yrs

Average Tenure

Experienced Management: FENC's management team is considered experienced (4.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Rostislav Raykov
CEO & Director15.4yrsUS$2.54m0.24%
$ 397.9k
Chris Rallis
Independent Director13.3yrsUS$173.18k0.19%
$ 312.8k
Khalid Islam
Independent Chairman of the Board10.7yrsUS$225.23k0.78%
$ 1.3m
Jodi Cook
Independent Director5.3yrsUS$153.81k0%
$ 0
Marco Brughera
Independent Director8.3yrsUS$166.31k0%
$ 0

10.7yrs

Average Tenure

69yo

Average Age

Experienced Board: FENC's board of directors are seasoned and experienced ( 10.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 09:31
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Fennec Pharmaceuticals Inc. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Difei YangAegis Capital Corporation
Naureen QuibriaCapital One Securities, Inc.
Chase KnickerbockerCraig-Hallum Capital Group LLC